Saturday, August 22, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Via News Knowledge File

Merck & Co., Inc.

organization80% conf.·synced Aug 22, 2026

Pharmaceutical company based in Rahway, NJ, known as MSD outside US and Canada

60
sourced metrics
659
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week High
152.55USD
Aug 21, 2026reference only
Price 52 Week Low
77.60USD
Aug 21, 2026reference only
Market Cap
376367033377USD
Aug 21, 2026reference only
Stock Price
152.55USD
Aug 21, 2026reference only
Stock Return Ytd
43.3%
Aug 21, 2026reference only
Shares Outstanding
2467171638.0shares
Jul 31, 2026reference only
Cost Of Revenue
4395000000.0USD
Jun 30, 2026reference only
Net Income
-1335000000.0USD
Jun 30, 2026reference only
Cash
6849000000.0USD
Jun 30, 2026reference only
Rd Expense
9741000000.0USD
Jun 30, 2026reference only
Revenue
16607000000.0USD
Jun 30, 2026reference only
Total Assets
129802000000.0USD
Jun 30, 2026reference only
Stockholders Equity
41933000000.0USD
Jun 30, 2026reference only
Eps
-0.54USD_per_share
Jun 30, 2026reference only
Capex
991000000.0USD
Mar 31, 2026reference only
Operating Cash Flow
3918000000.0USD
Mar 31, 2026reference only

Stated objectives

Enroll approximately 675 patients in KANDLELIT-007 Phase 3 trial

source
target: 675 patients stated

Evaluate progression-free survival as primary endpoint in PD-L1 TPS ≥1% patients in KANDLELIT-007

source
stated

Evaluate secondary endpoints including PFS in all patients, overall survival, objective response rate, duration of response, and safety in KANDLELIT-007

source
stated

Submit regulatory filings worldwide for KEYTRUDA + Padcev combination in muscle-invasive bladder cancer based on KEYNOTE-B15/EV-304 results

source
stated

Initiate second Merck-sponsored pivotal trial of zanzalintinib and belzutifan in RCC

source
stated

Full-year sales forecast

source
target: $64.5 billion to $65 billion by 2025-12-31 00:00:00stated

Full-year EPS forecast

source
target: $8.93 to $8.98 by 2025-12-31 00:00:00stated

Improving outcomes and addressing significant unmet needs for patients with hematologic neoplasms and malignancies

source
stated

Become the premier research-intensive biopharmaceutical company in the world

source
stated

Deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals

source
stated

Relationship graph · 659 connections

Developed by
266
Competes with
67
Employs
46
acquired by
42
Partnered with
41
Covered by
28
regulates
28
headquartered in
27
headquartered in
Rahway, New Jersey
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →